NORML

APRIL 30, 2020

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 345

Chronic Pain Clinical Trials Data Patients 345

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Otherside Farms

JANUARY 24, 2019

In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS).

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

FEBRUARY 2, 2022

The double-blind, randomised, placebo-controlled clinical trial took place over two years between 2017 and 2019 at the Center for Medicinal Cannabis Research at the University of California. As many patients use cannabis-based medicines to aid with sleep, the current detection window is of significant concern.

Medicine 52

Medicine Clinical Trials Consumption Sleep 52

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. The study, led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics , found anxiety was among the top three reasons for a medicinal cannabis prescription. The authors note, however, that the data doesn’t include patient outcomes.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards. Daily Cannabis Use as a Disqualifier.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. A promise made years ago.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Poster Number: INFO37.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. Common cannabinoids in cannabis. What does CBGA do?

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

SpeedWeed

MARCH 26, 2021

Several preliminary research studies have already suggested that CBD or other cannabinoids could help protect the lungs from COVID infections. This excessive inflammation, commonly known as a “cytokine storm,” is one of the leading causes of death in patients hospitalized with COVID. . View original article.

CBD 52

CBD Clinical Trials Cannabinoids Patients 52

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Healer

MARCH 26, 2021

Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. THC is the main psychoactive compound in marijuana, while CBD is a non-intoxicating cannabinoid found in the cannabis plant.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Greencamp

AUGUST 16, 2018

Because of the very rapid progression of ALS in the majority of patients, understanding how cannabis could help in the alleviation of symptoms is incredibly important for ALS sufferers. Both upper and lower motor neurons suffer severe damage in ALS patients. As few as 10% of ALS patients live longer than 10 years after being diagnosed.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Greencamp

FEBRUARY 2, 2019

Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. Cannabis as a palliative aid for HIV patients. What is HIV and how is it manifested? How classical pharmaceuticals fight HIV.

Marijuana 110

Marijuana Therapy Cannabinoids Patients 110